Design Therapeutics (DSGN) Return on Capital Employed (2021 - 2026)
Design Therapeutics (DSGN) reported Return on Capital Employed of 36.1% for Q1 2026, down 719.0% on a YoY basis from 5.83% in Q1 2025, and up 6.44% sequentially from 38.59% in Q4 2025.
Design Therapeutics (DSGN) Return on Capital Employed (2021 - 2026) Analysis & Trends
Design Therapeutics (DSGN) has 6 years of Return on Capital Employed data on file, last reported at 36.1% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 719.0% year-over-year to 36.1%; the trailing twelve-month figure through Mar 2026 stood at 36.1% (down 719.0% YoY), and the FY2025 full-year result was 35.15%, down 1137.0% from the prior year.
- Return on Capital Employed grew to 36.1% in Q1 2026, from 38.59% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 11.48% in Q1 2022 to a low of 38.59% in Q4 2025.
- A 5-year average of 25.98% and a median of 25.6% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 456 bps in 2024 and plunged 1428 bps in 2025, its largest moves.
- Tracing DSGN's Return on Capital Employed over 5 years: stood at 20.05% in 2022, then sank by 37 bps to 27.42% in 2023, then gained by 8 bps to 25.11% in 2024, then plunged by 54 bps to 38.59% in 2025, then advanced by 6 bps to 36.1% in 2026.
- Business Quant data shows DSGN's Return on Capital Employed at 36.1% in Q1 2026, 38.59% in Q4 2025, and 37.83% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Design Therapeutics | 714.48 Mn | 491.66 Mn | - | -36.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.10% |
| Dec 31, 2025 | -38.59% |
| Sep 30, 2025 | -37.83% |
| Jun 30, 2025 | -33.84% |
| Mar 31, 2025 | -28.92% |
| Dec 31, 2024 | -25.11% |
| Sep 30, 2024 | -23.55% |
| Jun 30, 2024 | -23.67% |
| Mar 31, 2024 | -25.60% |
| Dec 31, 2023 | -27.42% |
| Sep 30, 2023 | -28.11% |
| Jun 30, 2023 | -27.06% |
| Mar 31, 2023 | -23.43% |
| Dec 31, 2022 | -20.05% |
| Sep 30, 2022 | -16.91% |
| Jun 30, 2022 | -14.06% |
| Mar 31, 2022 | -11.48% |
| Dec 31, 2021 | -9.18% |
| Sep 30, 2021 | -7.19% |
| Jun 30, 2021 | -4.84% |